Patent application number | Description | Published |
20090105326 | Crystalline Chemotherapeutic - N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it is disclosed. | 04-23-2009 |
20090105486 | Crystalline Chemotherapeutic - N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea Tolueneate Crystalline Form 1, ways to make it and ways to use it are disclosed. | 04-23-2009 |
20090176784 | ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 07-09-2009 |
20090203664 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE - The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor. | 08-13-2009 |
20100048533 | LESTAURTINIB CRYSTALLINE FORM 1, CRYSTALLINE LESTAURIMIB ANHYDRATE AND AMORPHOUS LESTAURIMIB - Lestaurtinib Crystalline Form 1, isolated crystalline lestaurtinib anhydrate and amorphous lestaurtinib, processes to reproducibly make them and methods of treating patients using them. | 02-25-2010 |
20100048534 | CRYSTALLINE LESTAURTINIB HYDRATES AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMIACETONITRILEATE AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMITETRAHYDROFURANATE - Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemicetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate, processes to reproducibly make them and methods of treating patients using them are disclosed. | 02-25-2010 |
20100222358 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES - Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein. | 09-02-2010 |
20110281900 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 11-17-2011 |
20120189580 | ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 07-26-2012 |
20130096132 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE - The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. | 04-18-2013 |
20140303369 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 10-09-2014 |